Parabilis Medicines, Inc. (PBLS) Stock
Healthcare · Biotechnology · Member of Other US Stocks
Parabilis Medicines, Inc. (PBLS) closed at USD 25.89 on 2026-10-14, a change of -18.1 % over the past year, with a market capitalization of USD 3.11B.
Parabilis Medicines, Inc. recent closing prices
| Date | Close (USD) |
|---|---|
| 2026-10-14 | 25.89 |
| 2026-10-13 | 26.85 |
| 2026-10-12 | 28.95 |
| 2026-10-09 | 27.48 |
| 2026-10-08 | 28.09 |
| 2026-10-07 | 28.82 |
| 2026-10-06 | 28.86 |
The most recent trading day is not shown. For full charts and indicators use the analysis page.
Parabilis Medicines, Inc. key figures
- Previous close
- USD 25.89 (2026-10-14)
- 1-year change
- -18.1 %
- Market cap
- USD 3.11B
- Enterprise value
- USD 2.04B
- P/E ratio (trailing)
- -2.65
- P/E ratio (forward)
- -11.52
- EPS (trailing)
- -9.51
- EPS (forward)
- -2.19
- PEG ratio
- n/a
- Price to book
- 2.97
- Revenue growth
- n/a
- Earnings growth
- n/a
- Dividend per share (trailing)
- 0.00
- Short ratio
- 7.52
- Employees
- 145
- Analyst consensus (third-party)
- strong_buy
Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.
About Parabilis Medicines, Inc.
Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment. The company develops stabilized helical peptide therapeutics through its Helicon discovery platform, targeting proteins that are traditionally considered undruggable. Its pipeline includes functional inhibitors of intracellular protein-protein interactions, targeted protein degraders, and targeted radiopharmaceuticals, with a lead clinical program, FOG-001, that acts as a TCF-blocking beta-catenin inhibitor for cancer treatment. The company integrates artificial intelligence and data science into drug discovery, trial design, and clinical strategy optimization. Parabilis Medicines serves clients in the healthcare and life sciences industries, including clinical research organizations and medical professionals involved in oncology and cancer treatment. The company was founded in 2015 and is based in Cambridge, Massachusetts.
Technical indicators and comparison
Show RSI, MACD, EMA, CCI and ADX for Parabilis Medicines, Inc. and compare it with other stocks.
Analyze PBLSAll Other US Stocks stocksStock-scoring.com provides this page for information only. It is not investment advice or a recommendation to buy or sell Parabilis Medicines, Inc. shares.